TY  - JOUR
AU  - Fuster, Mark
AU  - Tran, Sheri
PY  - 2017
DA  - 2017/09/12
TI  - Malignancy in the Lung Transplant Population
JO  - OBM Transplantation
SP  - 004
VL  - 01
IS  - 03
AB  - The risk for developing a variety of malignancies is significantly elevated in the setting of lung transplantation. Malignancy remains among the three major causes of death in post-transplant recipients, and the relatively high risk of cancer development as well as metastatic aggression pose special threats to this population due to the need for continued immunosuppression. A variety of risks such as tobacco use and inflammatory lung diseases that led to the lung pathology prompting lung transplantation, in addition to immunosuppression and unique post-transplantat viral infections, introduce particularly high risks for carcinomas of the lung and head-and-neck, skin, endothelium (Kaposi sarcoma), colon and anogenital tracts, liver and kidneys. A uniquely high risk of developing non-hodgkins lymphoma or post-transplant lymphoproliferative disorder remains particularly challenging in this population. In this review, we discuss mechanisms leading to risk, details on malignancy presentation and characteristics, and special points on management and prevention in respective sections. In addition to highlighting key features, a major goal is to stimulate future advancements in the prevention and management of malignancy in this unique clinical setting.
SN  - 2577-5820
UR  - https://doi.org/10.21926/obm.transplant.1703004
DO  - 10.21926/obm.transplant.1703004
ID  - Fuster2017
ER  -